DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
First systemic evidence for safety of tPA in stroke patients with sickle cell disease
In the largest report on acute stroke in sickle cell disease to date, researchers at the Medical University of South Carolina and elsewhere provide the first systemic evidence for the safe use of tPA in stroke patients with sickle cell disease.
Adult patients with sickle cell disease (SCD) who experience a stroke caused by a clot (i.e., ischemic strokes or IS) can be treated safely with tissue plasminogen activator (tPA) if they qualify, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in the March 2017 issue of Stroke.
+myBinderRelated Content
-
education & researchAltered Oxygenation, Vascular and Ischemic Pain Responses in Adults with Sickle Cell AnemiaThe clinical hallmark of sickle cell ane...
-
education & researchFeasibility and acceptability of internet-delivered cognitive behavioral therapy for chronic pain in adolescents wit...Pain is a clinical hallmark of sickle ce...
-
Community CenterThe Role of Sleep Impairments on Pain Severity in Adults With Sickle Cell DiseaseSleep is a complex process and impairmen...
-
news & eventsMarijuana use common in sickle cell patients, highlighting need for more research, study showsMany sickle cell disease (SCD)...
-
news & eventsA new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
news & eventsCrizanlizumab lowers pain crises in at-risk sickle cell patients, ad-hoc trial data showNovartis’ investigational th...
-
news & events100 Years But Only One Drug: Sickle Cell Patients Wait For HelpLast week, 100,000 Americans with sickle...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.